Table 1.
Data in Patients With and Without Intracardiac Thrombus Detection (n=5648)
| Intracardiac thrombus (n=75) | No thrombus detection (n=5573) | Missing data, n (%) | |
|---|---|---|---|
| CRCS‐K (South Korea), n (%) | 27 (36.0) | 4456 (79.9) | 0 (0.00) |
| Age, median (IQR), y | 73 (70–81) | 75 (69–81) | 0 (0.00) |
| Women, n (%) | 35 (46.7) | 2615 (46.9) | 0 (0.00) |
| Body weight, median (IQR), kg | 57.8 (50–65) | 60 (51.3–68) | 55 (0.97) |
| Smoking, n (%) | 28 (37.3) | 1712 (30.8) | 7 (0.12) |
| NVAF known before index event, n (%) | 54 (72.0) | 3169 (56.9) | 0 (0.00) |
| Congestive heart failure, n (%) | 19 (25.3) | 446 (8.0) | 0 (0.00) |
| Vascular risk factor, n (%) | |||
| Hypertension | 54 (72.0) | 4075 (73.2) | 4 (0.07) |
| Diabetes mellitus | 20 (26.7) | 1488 (26.7) | 5 (0.09) |
| Hyperlipidemia | 30 (40.0) | 1625 (29.2) | 7 (0.12) |
| Clinical history, n (%) | |||
| Stroke before index event | 22 (29.3) | 1357 (24.4) | 5 (0.09) |
| Coronary heart disease | 10 (13.3) | 678 (12.2) | 0 (0.00) |
| Prestroke oral anticoagulants, n (%) | 30 (40.0) | 1099 (19.7) | 3 (0.05) |
| Prestroke antiplatelets, n (%) | 26 (34.7) | 2030 (36.5) | 3 (0.05) |
| Ischemic stroke as index event, n (%) | 69 (92.0) | 5412 (97.2) | 5 (0.09) |
| Baseline NIHSS score, median (IQR) | 5 (2–12) | 8 (3–16) | 0 (0.00) |
| Laboratory data, median (IQR) | |||
| White blood cell count, /µL | 6900 (5500–8830) | 7500 (6050–9500) | 7 (0.12) |
| Hemoglobin, g/dL | 13.9 (12.2–14.8) | 13.5 (12.2–14.7) | 8 (0.14) |
| Platelet count, ×103/µL | 178 (150–226) | 195 (160–236) | 10 (0.18) |
| Glucose, mg/dL | 128 (111–153) | 124 (105–153) | 188 (3.33) |
| PT‐INR | 1.06 (1.01–1.3) | 1.06 (1–1.15) | 61 (1.08) |
| Renal dysfunction, n (%)* | 3 (4.1) | 612 (11.1) | 66 (1.17) |
| TTE, n (%) | 71 (94.7) | 4096 (73.5) | 0 (0.00) |
| TEE, n (%) | 53 (70.7) | 626 (11.2) | 0 (0.00) |
| Medication at discharge, n (%) | |||
| Antiplatelets | 16 (21.3) | 1793 (32.2) | 0 (0.00) |
| Warfarin | 56 (74.7) | 3512 (63.0) | 0 (0.00) |
| Direct oral anticoagulants | 16 (21.3) | 565 (10.1) | 0 (0.00) |
| Dabigatran | 6 (8.0) | 259 (4.7) | |
| Apixaban | 0 (0.0) | 31 (0.6) | |
| Rivaroxaban | 10 (13.3) | 275 (4.9) | |
| Statins | 35 (46.7) | 3707 (66.5) | 0 (0.00) |
| Hospital stay, median (IQR), d | 18 (10–29) | 11 (7–20) | 0 (0.00) |
| mRS score at discharge, median (IQR) | 2 (1–3) | 3 (1–4) | 0 (0.00) |
CRCS‐K indicates Clinical Research Collaboration for Stroke in Korea; IQR, interquartile range; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; NVAF, nonvalvular atrial fibrillation; PT‐INR, prothrombin time/international normalized ratio; TEE, transesophageal echocardiography; and TTE, transthoracic echocardiography.
*
Renal dysfunction was defined as creatinine clearance <30 mL/min.